Painful Diabetic Neuropathy – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of painful diabetic neuropathy (PDN) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the prevalence of PDN for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.

Clarivate Epidemiology’s PDN forecast will answer the following questions:

• Of all people with PDN, how many in each country across the major mature pharmaceutical markets have been formally diagnosed?
• Of all people diagnosed with PDN, how many in each country across the major mature pharmaceutical markets are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of PDN over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts five PDN patient populations, as follows:

• Total prevalent cases of PDN due to diagnosed T1D and T2D.
• Diagnosed prevalent cases of PDN.
• Undiagnosed prevalent cases of PDN.
• Drug-treated prevalent cases of PDN.
• Non-drug-treated prevalent cases of PDN.

Note: coverage may vary by country.